Citius Oncology

Q3 FY2026 EarningsQ3 FY26 results significantly missed consensus estimates across all key financial metrics. Revenue of $1.49M was 40.25% below the $2.50M expected, reflecting a slower-than-anticipated commercial ramp-up for LYMPHIR since its December 2025 launch. Gross margin reached 67.1%, missing the 75.0% consensus by 7.93pct due to higher initial manufacturing and distribution costs. The GAAP net loss of $8.92M ($0.08 per share) exceeded the forecasted $7.55M loss, driven by elevated general and administrative expenses related to commercial expansion. Management issued a going concern warning, projecting that current funds are only sufficient to support operations through November 2026.